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DOI 10.1016/j.chembiol.2011.12.006In the coming years, a copy of your
personally sequenced genome could
become part of your medical record. As
high-quality sequencing information is
becoming increasingly available at lower
costs and at a faster pace than was
possible even a few years ago, geneticists
are talking about the possibility of whole-
genome sequencing becoming the stan-
dard of care in medicine.
Researchers use whole-genome se-
quencing to find associations between
singlenucleotidepolymorphisms,orSNPs,
and disease risk. These changes in the
genome account for most of what makes
humans differ from one another and could,Geneticists are preparing for the day when healthy patients,
perhaps starting at birth, have their genome sequenced as part
of routine care.for example, help explain why certain
chemotherapy works in some people but
not others or why some people are at
a higher risk for certain diseases like dia-
betes. However, technology seems to be
racing ahead of the ability to cope with so
much sequencing information. Experts
say that many issues need to be resolved,
such as how sequences acquired for
clinical purposes should be collected and
stored; how patient privacy will be ad-
dressed; how, when, and by whom, the
information will be accessed; and how the
general public and the medical community
become educated enough to used and
understand sequencing information.
There have already been a few in-
stances inwhichwhole-genomesequenc-
ing has been used in ways meaningful
enough to diagnose, manage, and treat
a complex disease. Earlier this year, the
team at the Genome Institute at Washing-
ton University in St. Louis, Missouri, used
information gleaned from whole-genome
sequencing to diagnose and treat a
woman with leukemia (Link et al., 2011).
At a cost of around $40,000, the teamsequenced thewhole genomeof awoman
at the request of her doctor. Her cancer
had features of two types of leukemia,
each of which would require different
treatment. The woman’s genome was
sequenced and analyzed in seven weeks,
which was enough time to determine that
she did not need a bone marrow trans-
plant. Timothy Ley, M.D., a professor of
medicine at the university who cares for
leukemia patients, says he plans to use
the same type of sequencing to help
clearly determine which patients with
acute myeloid leukemia (AML), a cancer
of a certain type of white blood cell, need
a bone marrow transplant. In about halfof people with AML, such a determination
isdifficult.He is currentlyworking toobtain
funding for that effort.
Geneticists are preparing for the day
when healthy patients, perhaps starting at
birth, have their genome sequenced as
part of routine care. At the joint meeting
of the International Congress of Human
Genetics and the American Society of
Human Genetics (ICHG/ASHG) held last
October inMontreal, participants in several
sessions discussed the advantages and
disadvantages of such a change in clinical
care,aswell as the technologicaladvances
that will make this effort possible. In one
session, industry leaders presented cur-
rent and future clinical applications of
next-generation technologies. In a plenary
debate, industry and academic leaders
discussed how next-generation sequenc-
ing could change medical genetics and
debated how quickly such technology
should be used as standard medical care.
Next Generation Sequencing
In an ICHG/ASGHmedia panel titled ‘‘The
Future of Next-Generation GenomicsChemistry & Biology 18, December 23, 2011 ªTools in the Clinic,’’ participants dis-
cussed the cost of whole-genome se-
quencing and also talked about steps
necessary to make the data relevant and
accessible to physicians. There’s been
much talk of the $1000 genome, but costs
will likely drop lower than that.
Roopom Banerjee, president and CEO
of RainDance Technologies (http://www.
raindancetech.com/), based in Lexington,
Massachusetts, calls the $1000 dollar
genome ‘‘so 2009,’’ but adds that $1000
dollars is still too high for the private pay
market and wondering whether a high-
quality sequence could be obtained for
that amount. He says he wants to see
whole-genome sequencing costs come
down to several hundred dollars. In the
meantime, improving the ability to inter-
pret the information would be useful.
The traffic jam slowing data is partly
caused by falling sequencing costs
and high-quality data, says Martin Reese,
Ph.D., cofounder and CEO of Omica
(http://www.omicia.com/). An infrastruc-
ture that includes software engineering,
informatics, and interpretation at a speed
that is clinically relevant will allow physi-
cians to focus on the clinical aspects of
sequencing information.
A near-term clinical application of
the third generation sequencing tech-
nology is underway at Pacific Biosciences
in Menlo Park, California (http://www.
pacificbiosciences.com/). One effort by
the company is applying targeted ge-
nome sequencing (choosing a specific
part of the genome on which to focus
a search) for the metabolic screening of
newborns, a program the company an-
nounced recently would start at Mount
Sinai Medical Center in New York.
Eric Schadt, Ph.D., CSO at Pacific
Biosciences and director of the Institute
for Genomics and Multiscale Biology at
Mount Sinai, says the technology can
also be used to turn infection samples
around quickly in hospitals by monitoring
the surfaces in intensive care units and2011 Elsevier Ltd All rights reserved 1513
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sequencing the samples in the same day.
Schadt says at the end of the day, infor-
mation from whole-genome sequencing
will have to be integrated with metabo-
lites, proteins, and RNA. ‘‘We view DNA
as a series of letters, but that is wrong.
There are chemical modifications to these
bases that can alter their chemical com-
position and change how genes act.un-
derstanding these interactions is critical
to understanding the genome. We’re just
scratching the surface of what needs to
be detectable from the third generation
sequencing technologies,’’ says Schadt.
Brakes or Accelerator on the
Translational Highway?
The impact that an abundance of
sequencing information will have on the
healthcare community and on society
goes beyond what technological ad-
vances are capable of accomplishing. At
the plenary debate session, ‘‘Current
and Emerging Sequencing Technologies:
Changing the Practice of Medical Genet-
ics,’’ experts in the public and private
sector tackled the societal issues of using
whole-genome sequencing in the clinic.
Although doctors other than medical ge-
neticists can order genetic tests, primary
care physicians may not be able to inter-
pret the sequencing results or understand
that variations in the genome (or SNPs)
may not always be linked to a particular
disease risk.
The debate centered on the ethical and
societal issues that need to be addressed,
such as the fact that genetic counselors
are already in short supply and that
insurers may not want to reimburse for1514 Chemistry & Biology 18, December 23,testing. Some panelists expressed con-
cern that the public and even the health
care community are not educated well
enough in genetics. Others worried that
that geneticists could be over promising
the ability of whole-genome sequenc-
ing because the ‘‘translation highway’’
doesn’t just go from the patient to the
technology to the doctor and then back
to the patient, but that the implications
of using whole-genome sequencing in
medical care represent a complex issue
that reaches into all of society.
Louanne Hudgins, M.D., FACMG, a
practicing clinical geneticist at Stanford
University in Palo Alto, CA, says that the
need for a better public understanding of
genetics reaches into the medical
community, as well. It’s easy for doctors
other than geneticists to order genetic
tests but that ‘‘primary care physicians
are ill prepared to interpret sequencing
results. I get calls from doctors who
don’t understand the difference between
genes and chromosomes,’’ says Hudgins.
Furthermore, Hudgins says that insurance
providers may not want to cover the cost
of whole genome sequencing.
On the technical side, interpreting the
three to four million variants found in
genomes, along with nonsense muta-
tions, also needs to be addressed.
Not everyone on the panel urged
caution. Radoje Drmanac, Ph.D., CSO
and cofounder of Complete Genomics, a
whole-genome sequencing company in
Mountain View, California (http://www.
completegenomics.com), calls for whole-
genomesequencing for everyone, starting
at birth. ‘‘We should celebrate our new
ability to sequence complete personal2011 ª2011 Elsevier Ltd All rights reservedgenomes because we didn’t have that a
few years ago,’’ he says. Drmanac adds
that Complete Genomics is on track to
sequence over 3,000 personal genomes
by the end of 2011. Because next-genera-
tion sequencing technology is scalable,
the next three or four years should
bring the ability to sequence one million
genomes per year at an affordable cost
says same Drmanac. That number is
necessary to make whole-genome se-
quencing clinically relevant because the
database of personal genomes needs to
reflect the ethnic diversity of the world
population, and there are millions of
newborns per year.
He advocates for obtaining whole-
genome sequencing as early as possible,
on newborns and even as early as in vitro
fertilization, when applicable. Whole ge-
nomes are needed, continues Drmanac,
because genes and genome regulatory
networks are so intertwined that all
of the information is necessary to help
provide the context necessary to interpret
biology of cells and organism.
‘‘There’s no deeper genetic level than
the complete genome sequence,’’ says
Drmanac.REFERENCE
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